Promoting research partnerships 

to improve veterans’ health

DoD Lung Cancer Research Programs Funding Opportunities

4 May 2018 10:00 AM | Hawk Tran (Administrator)

FY18 LCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

 

Applications submitted to the FY18 LCRP must address at least one of the eight Areas of Emphasis listed below:

 

  • Identify, develop, or optimize noninvasive or minimally invasive tools to improve the detection of the initial stages of lung cancer, such as, but not limited to, optimizing strategies for management of indeterminate nodules.

·         Identify, develop, and/or build upon already existing tools for screening or early detection of lung cancer. Screening may include, but is not limited to, imaging modalities, biomarkers, genetics/genomics/proteomics/metabolomics/transcriptomics, and assessment of risk factors.

·         Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.

·         Identify innovative strategies for prevention and treatment of lung cancer.

·         Understand predictive markers to identify responders and nonresponders.

·         Understand mechanisms of resistance to treatment (primary and secondary).

·         Understand contributors to lung cancer development other than tobacco.

·         Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management).

http://cdmrp.army.mil/funding/lcrp

Concept Award – Letter of Intent due July 26, 2018

·         All investigators at or above the level of postdoctoral fellow (or equivalent)

·         Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer

  • Emphasis on innovation
  • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b) or be eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
  • Clinical trials not allowed

·         Preliminary data discouraged (not consistent with intent of award mechanism)

·         Military relevance strongly encouraged

  • Maximum funding of $100,000 in direct costs (plus indirect costs)

·         Period of performance should not exceed 1 year

 

Career Development Award – Letter of Intent due September 6, 2018

·         Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment

·         Must not have received a Career Development Award previously from any program within the Congressionally Directed Medical Research Programs.

·         Must not have received more than $300,000 in total direct costs for previous or concurrent lung cancer research as a PI of one of more federally or privately funded, non-mentored, peer-reviewed grants

·         Mentor:  At or above the level of Associate Professor (or equivalent);

·         Must have a  strong publication and funding record in lung cancer research

·         Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher

·         Clinical trials not allowed

·         Preliminary data not required

·         Military relevance strongly encouraged

·         Maximum funding of $250,000 in direct costs (plus indirect costs)

·         Period of performance should not exceed 2 years

 

Idea Development Award – Preproposal due June 26, 2018

  • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or
  • New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

o   Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award

o   Be within 10 years of first faculty appointment (or equivalent)

  • Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research
  • Emphasis on innovation and impact
  • New Investigators: Supports applicants early in their faculty appointments or in the process of developing independent research careers
  • Clinical trials not allowed
  • Preliminary data required, but may be from outside of lung cancer

·         Military relevance strongly encouraged

·         Maximum funding of $350,000 in direct costs (plus indirect costs)

·         Period of performance should not exceed 2 years

 

Investigator-Initiated Translational Research Award – Preproposal due June 26, 2018

  • Independent investigators at or above the level of Assistant Professor (or equivalent)
  • Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations
  • Intended to fund a broad range of translational studies.
  • Clinical trials not allowed.
  • Preliminary Date required, but may be from outside of lung cancer.
  • Military relevance strongly encouraged.

·         Maximum funding of $400,000 in direct costs (plus indirect costs)

  • Period of performance should not exceed 2 years

 

Translational Research Partnership Award – Preproposal due June 26, 2018

  • Investigators at or above the level of Assistant Professor (or equivalent)
  • Supports partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications
  • One partner is strongly encouraged to be from a Department of Defense military treatment facility or laboratory, or Veterans Affairs medical center or research laboratory.
  • Non-Traditional Partnerships are encouraged.
  • Clinical trials are allowed.
  • Preliminary data required, but may be from outside of lung cancer
  • Maximum combined funding of $900,000 in direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
  • Military relevance strongly encouraged

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software